down arrow

TRxADE HEALTH, Inc.

  • Market Cap: N/A
  • Industry: Miscellaneous
  • ISIN: US89846A4058
USD
0.61
0.05 (9.56%)

Dec 04

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

0.590.62

52 Week

0.468.23
Valuation
Technical
Day's Volume

CASH

60.17 k

Shareholding (Mar 2025)

FII

0.07%

Held by 6 FIIs

DII

99.43%

Held by 1 DIIs

Promoter

0.00%

How big is TRxADE HEALTH, Inc.?

22-Jun-2025

As of Jun 18, TRxADE HEALTH, Inc. has a market capitalization of 8.63 million and reported net sales of 0.14 million with a net profit of -14.66 million over the latest four quarters. Shareholder's funds are at 79.07 million and total assets at 107.38 million as of Dec 24.

As of Jun 18, TRxADE HEALTH, Inc. has a market capitalization of 8.63 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the sum of Net Sales for the latest four quarters is 0.14 million, while the sum of Net Profit for the same period is -14.66 million.<BR><BR>As of Dec 24, the reporting period shows Shareholder's Funds at 79.07 million and Total Assets at 107.38 million.

Read More

What does TRxADE HEALTH, Inc. do?

22-Jun-2025

TRxADE HEALTH, Inc. is an integrated pharmaceutical services company in the micro-cap market, currently reporting net sales of $0 million and a net loss of $3 million as of March 2025. The company has a market cap of $8.63 million and a dividend yield of 21.67%.

Overview:<BR>TRxADE HEALTH, Inc. is an integrated pharmaceutical services company that operates within the miscellaneous industry and falls under the micro-cap market category.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 0 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -3 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 8.63 Million (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 21.67% <BR>Debt Equity: 0.02 <BR>Return on Equity: -17.32% <BR>Price to Book: 0.11<BR><BR>Contact Details:<BR>Address: 3840 Land O Lakes Blvd, LAND O LAKES FL: 34639-4418 <BR>Tel: 1 813 6013533 <BR>Fax: 1 800 2535177 <BR>Website: https://www.trxadegroup.com/

Read More

Who are in the management team of TRxADE HEALTH, Inc.?

22-Jun-2025

As of March 2022, the management team of TRxADE HEALTH, Inc. includes Mr. Surendra Ajjarapu (Chairman, CEO, Secretary), Mr. Prashant Patel (President, COO, Director), and Independent Directors Mr. Donald Fell, Mr. Michael Peterson, and Dr. Pamela Tenaerts. They oversee the company's strategic direction and operations.

As of March 2022, the management team of TRxADE HEALTH, Inc. includes the following individuals:<BR><BR>- Mr. Surendra Ajjarapu, who serves as the Chairman of the Board, Chief Executive Officer, and Secretary.<BR>- Mr. Prashant Patel, who is the President, Chief Operating Officer, and a Director.<BR>- Mr. Donald Fell, who is an Independent Director.<BR>- Mr. Michael Peterson, who is also an Independent Director.<BR>- Dr. Pamela Tenaerts, who serves as an Independent Director. <BR><BR>This team is responsible for guiding the company's strategic direction and operations.

Read More

Is TRxADE HEALTH, Inc. overvalued or undervalued?

25-Jun-2025

As of March 26, 2025, TRxADE HEALTH, Inc. is considered overvalued and has deteriorated to a "does not qualify" rating due to poor financial metrics, including a Price to Book Value of 0.12, negative ROCE and ROE, and significant underperformance compared to peers and the S&P 500.

As of 26 March 2025, the valuation grade for TRxADE HEALTH, Inc. has moved from risky to does not qualify, indicating a significant deterioration in its financial standing. The company appears to be overvalued given its current metrics, particularly with a Price to Book Value of 0.12 and an EV to Sales ratio of 11.15, which suggests that the market is pricing it excessively relative to its sales performance. Additionally, the company has a negative ROCE of -15.44% and a negative ROE of -17.32%, further underscoring its financial struggles.<BR><BR>In comparison to peers, TRxADE HEALTH, Inc. is underperforming against companies like SilverSun Technologies, Inc., which has a P/E ratio of 318.49, and Ashford, Inc., with an EV to EBITDA of 1.88. The stark contrast in these ratios highlights the challenges TRxADE faces in attracting investor confidence. Furthermore, the company's stock has significantly underperformed against the S&P 500, with a year-to-date return of -85.12% compared to the index's 2.44%. Overall, TRxADE HEALTH, Inc. is deemed overvalued in its current state.

Read More

Is TRxADE HEALTH, Inc. technically bullish or bearish?

20-Sep-2025

As of June 4, 2025, TRxADE HEALTH, Inc. shows a mildly bearish trend with mixed indicators, including mildly bullish MACD signals but bearish daily moving averages and Bollinger Bands, and has significantly underperformed the S&P 500 with a year-to-date return of -85.31%.

As of 4 June 2025, the technical trend for TRxADE HEALTH, Inc. has changed from bearish to mildly bearish. The weekly MACD is mildly bullish, while the monthly MACD is also mildly bullish, indicating some positive momentum. However, the daily moving averages are bearish, and the Bollinger Bands are bearish on both weekly and monthly time frames. The KST shows a bullish signal weekly but is bearish monthly, and the Dow Theory indicates a mildly bearish stance weekly with no trend monthly. The OBV is mildly bearish in both weekly and monthly assessments.<BR><BR>In terms of performance, TRxADE HEALTH has significantly underperformed compared to the S&P 500, with a year-to-date return of -85.31% versus the S&P 500's 12.22%, and a one-year return of -87.12% compared to the S&P 500's 17.14%. Overall, the current technical stance is mildly bearish, reflecting a mix of indicators with some positive signals but dominated by bearish trends.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Miscellaneous

stock-summary
Market cap

USD 17 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

0.05

stock-summary
Return on Equity

-24.05%

stock-summary
Price to Book

0.22

Revenue and Profits:
Net Sales:
(Quarterly Results - Jun 2025)
Net Profit:
-7 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-37.5%
0%
-37.5%
6 Months
-28.1%
0%
-28.1%
1 Year
-91.81%
0%
-91.81%
2 Years
-89.85%
0%
-89.85%
3 Years
18.59%
0%
18.59%
4 Years
-98.48%
0%
-98.48%
5 Years
-99.28%
0%
-99.28%

TRxADE HEALTH, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News

Is TRxADE HEALTH, Inc. technically bullish or bearish?

As of 4 June 2025, the technical trend for TRxADE HEALTH, Inc. has changed from bearish to mildly bearish. The weekly MACD is mildly bullish, while the monthly MACD is also mildly bullish, indicating some positive momentum. However, the daily moving averages are bearish, and the Bollinger Bands are bearish on both weekly and monthly time frames. The KST shows a bullish signal weekly but is bearish monthly, and the Dow Theory indicates a mildly bearish stance weekly with no trend monthly. The OBV is mildly bearish in both weekly and monthly assessments. In terms of performance, TRxADE HEALTH has significantly underperformed compared to the S&P 500, with a year-to-date return of -85.31% versus the S&P 500's 12.22%, and a one-year return of -87.12% compared to the S&P 500's 17.14%. Overall, the current technical stance is mildly bearish, reflecting a mix of indicators with some positive signals but dominated ...

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
-60.07%
EBIT Growth (5y)
-272.51%
EBIT to Interest (avg)
-4.67
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
0.02
Sales to Capital Employed (avg)
0.44
Tax Ratio
3.51%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
1.90%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
0.12
EV to EBIT
-0.87
EV to EBITDA
-0.88
EV to Capital Employed
0.13
EV to Sales
11.15
PEG Ratio
NA
Dividend Yield
19.63%
ROCE (Latest)
-15.44%
ROE (Latest)
-17.32%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Bearish
Dow Theory
Mildly Bullish
No Trend
OBV
Mildly Bullish
Mildly Bullish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 2 Schemes (0.51%)

Foreign Institutions

Held by 6 Foreign Institutions (0.07%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 0.00% vs -100.00% in Mar 2025",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is -116.13% vs 54.41% in Mar 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-5.10",
          "val2": "-3.60",
          "chgp": "-41.67%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.70",
          "val2": "0.70",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-0.60",
          "val2": "1.20",
          "chgp": "-150.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-6.70",
          "val2": "-3.10",
          "chgp": "-116.13%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "-348,149.40%",
          "chgp": "34,814.94%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is -92.86% vs -86.41% in Dec 2023",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -114.12% vs -254.17% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.10",
          "val2": "1.40",
          "chgp": "-92.86%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-14.60",
          "val2": "-3.30",
          "chgp": "-342.42%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "1.30",
          "val2": "1.10",
          "chgp": "18.18%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-2.50",
          "val2": "-0.10",
          "chgp": "-2,400.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-18.20",
          "val2": "-8.50",
          "chgp": "-114.12%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-107,587.00%",
          "val2": "-3,223.60%",
          "chgp": "-10,436.34%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQstock-summary
Jun'25
Mar'25
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-5.10
-3.60
-41.67%
Interest
0.70
0.70
Exceptional Items
-0.60
1.20
-150.00%
Consolidate Net Profit
-6.70
-3.10
-116.13%
Operating Profit Margin (Excl OI)
0.00%
-348,149.40%
34,814.94%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

QoQ Growth in quarter ended Jun 2025 is 0.00% vs -100.00% in Mar 2025

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Jun 2025 is -116.13% vs 54.41% in Mar 2025

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
0.10
1.40
-92.86%
Operating Profit (PBDIT) excl Other Income
-14.60
-3.30
-342.42%
Interest
1.30
1.10
18.18%
Exceptional Items
-2.50
-0.10
-2,400.00%
Consolidate Net Profit
-18.20
-8.50
-114.12%
Operating Profit Margin (Excl OI)
-107,587.00%
-3,223.60%
-10,436.34%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is -92.86% vs -86.41% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -114.12% vs -254.17% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About TRxADE HEALTH, Inc. stock-summary
stock-summary
TRxADE HEALTH, Inc.
Miscellaneous
Trxade Group, Inc. is an integrated pharmaceutical services company that combines a Web-based purchasing platform for transactions between independent pharmacists and drug manufacturers. The Company provides specialty pharmacy, warehouse and drug delivery services for consumers. It provides e-commerce technology platform with buyer/seller pricing algorithms, product availability and data analytics features. It operates a specialty pharmacy for consumers throughout the United States, as well as a Delivmeds mobile application (delivmeds.com), and telemedicine portal (bonumhealth.com) that enables home delivery.
Company Coordinates stock-summary
Company Details
3840 Land O Lakes Blvd , LAND O LAKES FL : 34639-4418
stock-summary
Tel: 1 813 6013533
stock-summary
https://www.trxadegroup.com/
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."